Talvy | $2,000,000 | (Mar 11, 2026)
Unreasonable Labs | $13,500,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
Certified by Founder
Lodge
Alveus Therapeutics Inc
start up
United States
- Philadelphia, Pennsylvania
- 09/01/2026
- Series A
- $160,000,000
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
- Industry Biotechnology Research
- Website https://alveustx.com/
- LinkedIn https://www.linkedin.com/company/alveus-therapeutics/
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)